Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04737174
Other study ID # EST-481 2020-Onco-101-HGG
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date March 25, 2021
Est. completion date April 2022

Study information

Verified date March 2022
Source ES Therapeutics Australia Pty Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 2A single-arm exploratory clinical study in up to 12 adult subjects aged 18 and older with primary glioma, IDH1 mutation, and uncontrolled focal-onset seizure activity to determine the potential efficacy, safety and pharmacokinetics of ES-481 as adjunctive therapy in glioma-associated epilepsy and to assess for potential anti-tumorigenic effects.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2022
Est. primary completion date October 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects greater than 18 years of age 2. Subjects with brain tumour-related epilepsy 3. Subjects with a history of uncontrolled seizures (at least three focal-onset seizure per month over the last 28 days) 4. Subjects currently being treated with at least one appropriate AED 5. Subjects who have had a brain MRI performed in the last three months preceding the signing of informed consent 6. Subjects with primary brain tumour with an IDH1 mutation (to be determined during the screening period) 7. Subjects with satisfactory hematologic, renal and liver function, as assessed by the Principal Investigator 8. Subject with a Karnofsky performance scale index (KPD) of > 70% 9. An expected survival time > 6 months 10. A female subject is eligible to participate if she is not pregnant by serum pregnancy test, not breastfeeding, and at least 1 of the following conditions applies: 1. Not of childbearing potential, defined as surgically sterile (documented hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or postmenopausal (no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy; however, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient) 2. Of childbearing potential and agrees to use a highly effective method of contraception consistently during the 4-week dose escalation, 16-week treatment, and 4-week washout periods; and for at least 30 days after the last dose of study treatment 11. A male patient with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during 4-week dose escalation, 16-week treatment, and 4-week washout periods; and for at least 30 days after the last dose of study treatment and refrains from donating sperm during this period 12. Willing to participate in the study and willing to provide written signed informed consent. Exclusion Criteria: 1. Urgent need for surgical intervention 2. Alanine aminotransferase or aspartate aminotransferase > 10 times the upper reference limit at the screening visit 3. Estimated glomerular filtration rate < 60 mL/min (calculated using the using the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation) at the screening visit 4. Any haematological National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0 Grade = 3 (with the exception of alopecia) at the screening visit 5. Factors that significantly affect oral drug absorption, such as inability to swallow, chronic diarrhoea, short bowel syndrome, and/or intestinal obstruction 6. Hypertension that cannot be reduced to normal range with antihypertensive medication (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg) 7. Concurrent active cancer that requires non-surgical treatment (e.g., chemotherapy, radiotherapy, adjuvant therapy) 8. History of severe cardiovascular disease: myocardial ischemia or myocardial infarction of Grade 2 or above, poorly controlled arrhythmia (including QTc interval =450 ms for men, =470 ms for women); according to New York Heart Association standards, Grade 3 or 4 cardiac insufficiency, or colour doppler ultrasound examination of the left ventricular ejection fraction < 50% as assessed at the screening visit 9. In the Investigators opinion, the subject's involvement may affect the progress of the clinical study and/or the determination of the research results, and/or considers them unsuitable for inclusion 10. Previously suffered severe cardiovascular disease: myocardial ischemia or myocardial infarction of Grade 2 or above, poorly controlled arrhythmia (including QTc interval =450 ms for men, =470 ms for women); according to New York Heart Association standards, Grade 3 or 4 cardiac insufficiency, or color doppler ultrasound examination of the left ventricular ejection fraction < 50%. 11. Investigator judges that may affect the progress of the clinical study and/or the determination of the research results, and/or considers them unsuitable for inclusion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ES-481
28-day screening period followed by 4-week dose escalation period followed by 16-week treatment period followed by 4-week dose washout period

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
ES Therapeutics Australia Pty Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Electroencephalogram Monitoring of epileptiform interictal and seizure discharge Continual 24 hours
Primary Subject Captured Seizure Activity Subjects will keep daily diary of seizure activity Continual 24 hour
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03548779 - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2 N/A
Completed NCT05605301 - Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy Phase 2
Completed NCT05257811 - Earbud EEG Feasibility Study
Completed NCT05066880 - Yoga and Aerobic Exercise in Epilepsy N/A
Recruiting NCT06278428 - Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age
Terminated NCT04639310 - XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy Phase 3
Not yet recruiting NCT06275685 - Forecasting Seizures Using Intelligent Wearable Technology for Health Tracking N/A
Completed NCT04822662 - The Individual and Family Self Management Theory Based Epilepsy Education Program's Effectiveness N/A
Recruiting NCT04759196 - Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas Phase 4
Completed NCT04171934 - Clinical Validation of a Video-based Epilepsy Examination Service
Recruiting NCT04569708 - Sleep Spindles and Memory in Rolandic Epilepsy N/A
Completed NCT04311151 - Impact of Self-visualization of Epileptic Seizures on Patients' Perception of the Disease and Risk Behavior N/A
Not yet recruiting NCT05635396 - Seizures Detection in Real Life Setting N/A
Completed NCT05675254 - The Prevalence and Risk Factors of Coagulopathy in Pediatric Epilepsy Surgery Patients
Terminated NCT04912856 - An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE Phase 3
Recruiting NCT04221282 - ZEBinix® Retention Rate in Epilepsy in Elderly Patients